GSK plc reported positive results from the ANCHOR-1 and ANCHOR-2 trials on March 1, 2025, showing the drug depemokimab significantly improves nasal polyp size and obstruction in patients with chronic rhinosinusitis, with a reduction from baseline versus placebo.